Comparative Stroke, Bleeding, and Mortality

ARTICLE IN PRESS Supplementary Table 7 Adjusted Hazard Ratios (95% Confidence Intervals) for Pairwise Comparisons of Each NOAC vs Warfarin and Each NOAC vs Each Other NOAC, for the Outcome of Major Extracranial Bleeding and Major Gastrointestinal Bleeding, By Days on Anticoagulant Therapy Days on Treatment Hazard Ratio (95% Confidence Interval) Major extracranial bleeding NOAC vs warfarin Dabigatran vs warfarin 1-30 0.91 (0.79-1.04) 31-60 1.10 (0.89-1.35) 61+ 1.16 (1.02-1.32) Rivaroxaban vs warfarin 1-30 1.18 (1.05-1.33) 31-60 1.79 (1.51-2.11) 61+ 1.43 (1.28-1.59) Apixaban vs warfarin 1-30 0.48 (0.40-0.58) 31-60 0.62 (0.48-0.81) 61+ 0.49 (0.40-0.61) NOAC vs NOAC Rivaroxaban vs dabigatran 1-30 1.30 (1.12-1.50) 31-60 1.63 (1.32-2.01) 61 1.23 (1.08-1.40) Rivaroxaban vs apixaban 1-30 2.45 (2.03-2.96) 31-60 2.87 (2.19-3.76) 61+ 2.89 (2.34-3.57) Dabigatran vs apixaban 1-30 1.89 (1.54-2.30) 31-60 1.76 (1.31-2.37) 61+ 2.36 (1.89-2.94) Major gastrointestinal bleeding NOAC vs warfarin Dabigatran vs warfarin 1-30 0.98 (0.85-1.14) 31-60 1.19 (0.94-1.49) 61+ 1.35 (1.17-1.55) Rivaroxaban vs warfarin 1-30 1.24 (1.09-1.40) 31-60 1.87 (1.56-2.25) 61+ 1.57 (1.39-1.77) Apixaban vs warfarin 1-30 0.50 (0.41-0.61) 31-60 0.57 (0.42-0.77) 61+ 0.52 (0.41-0.66) NOAC vs NOAC Rivaroxaban vs dabigatran 1-30 1.26 (1.08-1.47) 31-60 1.58 (1.26-1.99) 61 1.16 (1.01-1.34) Rivaroxaban vs apixaban 1-30 2.50 (2.03-3.07) 31-60 3.30 (2.42-4.51) 61+ 3.01 (2.38-3.81) Dabigatran vs apixaban 1-30 1.99 (1.60-2.47) 31-60 2.09 (1.49-2.93) 61+ 2.59 (2.03-3.30) NOAC = nonvitamin K antagonist oral anticoagulant. 9.e7 The American Journal of Medicine, Vol 000, No 000, && 2019